Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Uma M. Borate,Yazan F. Madanat,Cristina Tognon, Shikha Mishra,Andy Kaempf,Prapti A. Patel,Stephen E. Kurtz,Kara Johnson,Sumithira Vasu,Sharyn D. Baker, Bridget A Robinson,Tania Q Vu, Christopher A. Eide,Jessica Minnier, Yiqing Zhang, Peter Clement,Sammantha Avaylon,Thomas Jacob,Rachel Cook,Arpita Gandhi

Blood（2023）

引用 0|浏览6

暂无评分

摘要

Introduction : A functional small molecule screen on a large cohort of primary AML patient samples revealed that the combination of Ruxolitinib (Rux) and Venetoclax (Ven) exhibited ex vivo efficacy and synergy in both newly diagnosed and R/R AML. This observation motivated a Phase I multi-center trial to evaluate Rux+Ven in R/R AML, for which we now report complete toxicity and efficacy data for 30 subjects.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要